Myeloma

He dreams that this ever-growing body of knowledge will progressively improve the ability to understand and treat cancer; multiple myeloma has been at the center of this dream.

Some patients are at higher risk of infection, so it’s critical that they keep their care team up to date on any symptoms.

The past 20 years have brought great advances to advocacy groups, helping to improve patients’ quality of life. But more work is needed to raise awareness in underserved groups.

It is important that caregivers take care of not only the patient, but also themselves, as the diagnosis may affect their mental health.

From updates on clinical trials to a podcast where an oncology nurse shares how her son’s leukemia diagnosis changed her life, here are CURE®’s top blood cancer articles from the year 2022.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

CURE®’s Multiple Myeloma Heroes® Award Program honors and gives thanks to those who have made it their mission to change the lives of patients with multiple myeloma.

Watch Dr. Francesco Maura, Dr. Marcella Kaddoura and Mary DeRome answer questions about the future of myeloma during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Marcella Kaddoura, from Miami Sylvester Comprehensive Cancer Center, discuss targeting myeloma with small molecules with precision medicine during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Francesco Maura, from Miami Sylvester Comprehensive Cancer Center, discuss how personalized prediction models can be used to identify the best treatments during the CURE® Educated Patient Multiple Myeloma Summit.

Watch Valarie Traynham, of the HealthTree Foundation, discuss the long-term journey of the disease and disparities still seen during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian and Dr. Benjamin Diamond answer questions about therapeutic options during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Benjamin T. Diamond, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of sustained MRD negativity during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian, from the Sylvester Comprehensive Cancer Center at the University of Miami, discuss available immunotherapy options during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren and Dr. David Coffey answer questions about novel treatments and the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. David Coffey, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss the role of a healthy immune system during the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. C. Ola Landgren, from Sylvester Comprehensive Cancer Center at the University of Miami, discuss novel treatments for newly diagnosed patients during the CURE® Educated Patient® Multiple Myeloma Summit.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their vice president of support, Robin Tuohy about the importance of support for patients with multiple myeloma, and their caregivers.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about clinical trials for patients with multiple myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about disparities in the multiple myeloma space.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple myeloma, MGUS and smoldering myeloma.

As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the risk of infection for patients with multiple myeloma.

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed.

Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma.